208 related articles for article (PubMed ID: 22742971)
21. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
22. A case report of nephrotic syndrome due to intake of certolizumab pegol in a patient with Crohn's disease.
Leong J; Fung-Liu B
Am J Gastroenterol; 2010 Jan; 105(1):234. PubMed ID: 20054326
[No Abstract] [Full Text] [Related]
23. Successful treatment of fistulizing Crohn's disease with certolizumab pegol.
Danese S; Stefanelli T; Omodei P; Zatelli S; Bonifacio C; Balzarini L; Repici A; Malesci A
Inflamm Bowel Dis; 2008 Feb; 14(2):292-3. PubMed ID: 17932987
[No Abstract] [Full Text] [Related]
24. TNF inhibitors for Crohn's disease: when, which, and for how long.
Med Lett Drugs Ther; 2013 Dec; 55(1432):102-3. PubMed ID: 24419244
[No Abstract] [Full Text] [Related]
25. [Compassionate use of certolizumab in Crohn's disease].
Planas-Giner A; Salort-Llorca C; Garriga-Biosca R; Esteve-Comas M
Farm Hosp; 2008; 32(2):127-9. PubMed ID: 18783714
[No Abstract] [Full Text] [Related]
26. How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients.
Aletaha D
BioDrugs; 2014 Apr; 28 Suppl 1():S3-4. PubMed ID: 24687233
[No Abstract] [Full Text] [Related]
27. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
Pasut G
BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
[TBL] [Abstract][Full Text] [Related]
28. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
29. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature.
Hudesman D; Lichtiger S; Sands B
Inflamm Bowel Dis; 2013 Mar; 19(3):644-9. PubMed ID: 23314243
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
Tun GS; Lobo AJ
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):317-27. PubMed ID: 25586216
[TBL] [Abstract][Full Text] [Related]
31. Anti-TNF antibodies for Crohn's disease.
Camilleri M
N Engl J Med; 2007 Oct; 357(16):1662; author reply 1662. PubMed ID: 17942882
[No Abstract] [Full Text] [Related]
32. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Lichtenstein GR; Thomsen OØ; Schreiber S; Lawrance IC; Hanauer SB; Bloomfield R; Sandborn WJ;
Clin Gastroenterol Hepatol; 2010 Jul; 8(7):600-9. PubMed ID: 20117244
[TBL] [Abstract][Full Text] [Related]
33. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.
Deeks ED
Drugs; 2013 Jan; 73(1):75-97. PubMed ID: 23338540
[TBL] [Abstract][Full Text] [Related]
34. Blaschkitis under certolizumab for rheumatoid arthritis.
Couderc M; Soubrier M
Joint Bone Spine; 2014 Jul; 81(4):372-3. PubMed ID: 24439961
[No Abstract] [Full Text] [Related]
35. Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case.
Mocciaro F; Renna S; Orlando A; Cottone M
Am J Gastroenterol; 2009 Nov; 104(11):2867-8. PubMed ID: 19888257
[No Abstract] [Full Text] [Related]
36. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease.
Desai A; Zator ZA; de Silva P; Nguyen DD; Korzenik J; Yajnik V; Ananthakrishnan AN
Inflamm Bowel Dis; 2013 Feb; 19(2):309-15. PubMed ID: 22605668
[TBL] [Abstract][Full Text] [Related]
37. Certolizumab pegol (CDP870) for treatment of Crohn's disease.
Sisson G; Harris A
Gastroenterology; 2006 Jan; 130(1):285-6; author reply 286. PubMed ID: 16401499
[No Abstract] [Full Text] [Related]
38. Letter: Effectiveness of split-dose certolizumab pegol for Crohn's disease.
Kane SV; Neis B; Becker BD; Bruining D; Faubion WA; Kisiel J; Loftus EV; Pardi D; Raffals L; Schroeder K; Tremaine WJ
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1412. PubMed ID: 24206378
[No Abstract] [Full Text] [Related]
39. Anti-TNF antibodies for Crohn's disease--in pursuit of the perfect clinical trial.
Lewis JD
N Engl J Med; 2007 Jul; 357(3):296-8. PubMed ID: 17634466
[No Abstract] [Full Text] [Related]
40. Certolizumab pegol in the treatment of Crohn's disease.
Ferrante M; Vermeire S; Rutgeerts P
Expert Opin Biol Ther; 2013 Apr; 13(4):595-605. PubMed ID: 23451881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
